Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jchf.2022.12.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
LncRNA NORAD sponging to miR-26b-5p represses the progression of Alzheimer's disease in vitro by upregulating MME expression.
Cytotechnology
February 2025
Department of Neurology, Hubei Provincial Hospital of Integrated Traditional and Western Medicine, Jianghan District, No. 11 Lingjiaohu Road, Wuhan, 430015 China.
Unlabelled: Alzheimer's disease (AD) is a progressive neurological condition that causes brain shrinkage and cell death. This study aimed to identify the role of the NORAD/miR-26b-5p axis in AD. StarBase was used to examine the binding sequences of miR-26b-5p to LncRNA NORAD or its target genes, which were verified by a double luciferase reporter assay.
View Article and Find Full Text PDFComprehensive review on neprilysin (NEP) inhibitors: design, structure-activity relationships, and clinical applications.
Front Pharmacol
December 2024
Department of Orthodontics, State Key Laboratory of Oral Diseases, West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China.
Neprilysin (NEP), a zinc-dependent membrane-bound metallopeptidase, regulates various bioactive peptides, particularly in kidneys, vascular endothelium, and the central nervous system. NEP's involvement in metabolizing natriuretic peptides, insulin, and enkephalins makes it a promising target for treating cardiovascular and Alzheimer's diseases. Several NEP inhibitors, such as sacubitril and omapatrilat, have been approved for clinical use, which inhibit NEP activity to prolong the bioactivity of beneficial peptides, thereby exerting therapeutic effects.
View Article and Find Full Text PDFAngiotensin Receptor-Neprilysin Inhibitor Prescribing Patterns in Patients Hospitalized for Heart Failure.
JAMA Cardiol
December 2024
Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, Los Angeles, California.
Importance: Angiotensin receptor-neprilysin inhibition (ARNI) improves mortality among patients with heart failure with reduced ejection fraction (HFrEF), ie, those with an EF of 40% or less.
Objective: To describe national longitudinal trends in ARNI prescribing patterns among hospitalized patients with HFrEF.
Design, Setting, And Participants: Using data from the Get With The Guidelines-Heart Failure (GWTG-HF) registry, hospitalized patients with HFrEF at 614 participating hospitals were identified.
Impact of Sacubitril/Valsartan in Improving Home Time for Patients With Heart Failure.
Cureus
November 2024
Cardiology, Fortis Hospital, Gurgaon, IND.
Article Synopsis
- Home time, or the duration patients with cardiovascular disease spend alive outside of healthcare institutions, is an essential aspect of recovery, particularly for heart failure (HF) patients, yet insufficiently studied in India where HF rates are increasing.
- Current literature falls short in identifying hospital-level trends and predictors of home time, which complicates the development of personalized care strategies to enhance health outcomes, functional status, and reduce hospitalization risks.
- While guideline-directed medical therapy, especially sacubitril/valsartan (an angiotensin receptor neprilysin inhibitor), is well-supported for improving life quality and reducing HF-related hospitalizations, its use remains low, indicating a critical need for better integration into clinical practice to improve patient recovery and home time post
The impact of angiotensin-receptor neprilysin inhibitors on cardiovascular events and solute transport function in peritoneal dialysis patients: a multicenter retrospective controlled study.
Ren Fail
December 2024
Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Background: Whether angiotensin receptor-neprilysin inhibitor (ARNI) can reduce the incidence of cardiovascular events and improve peritoneal function in peritoneal dialysis (PD) patients remains unclear. Thus, this study aims to clarify the role of ARNI in PD patients.
Methods: This was a multicenter retrospective study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!